20May

Rapid free light chain test granted registration in Brazil

AbingdonHealth

Seralite® – FLC is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.

This is a key registration for Seralite® – FLC and underpins the regional strategy for Latin America. In conjunction with Seralite® – FLC Serum, Seralite® – FLC LFD Controls and the ADxLR5® Reader System have also been granted registration. Latin America has a population of 606 million people and with a market size of more than US$2.4bn is a key emerging IVD market.

With this registration in Brazil, Seralite® – FLC is now available in 73 countries worldwide. Seralite® – FLC is distributed globally (with the exception of Benelux), by Sebia, the world leader in medical diagnostics for electrophoresis.

Fiona Smith, Sales and Marketing Director, Abingdon Health commented;

“The registration of Seralite® – FLC in Brazil is a milestone registration in South America and supports the global expansion Seralite® – FLC. Our aim is to make free light chain testing available to all clinical laboratories in all areas of the world thus improving patient access to this important diagnostic and monitoring tool for Multiple Myeloma.”

About Abingdon Health

Abingdon is a UK-based developer and manufacturer of lateral flow immunoassay tests and readers.

Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay. Internally Abingdon is focused on developing lateral flow assays in partnership with key opinion leaders that meet significant unmet needs.

Related

The TOPRA Annual Symposium

The TOPRA Annual Symposium is the largest forum for European regulatory professionals to meet up, di...

Read More >

DEMAND FOR GENETIC TESTING DRIVES GROWTH FOR AWARD WINNING ELUCIGENE DIAGNOSTICS

30 percent growth and innovation products wins Manchester company BVCA award. Having the right te...

Read More >

Free Workshop – “FIT to Practice?” Alpha Laboratories at ACB FOCUS 2018

Faecal Immunochemical Testing (FIT) is now an established diagnostic test that identifies the presen...

Read More >

Reduce Your Costs for Biological Sample Transport

How do you package your send-away pathology samples? Are you spending too much time and money on pac...

Read More >

Novodiag® launch, a new diagnostic solution for infectious diseases.

Espoo, Finland, January 3rd, 2018 - Mobidiag, a Finnish molecular diagnostics company, launches Novo...

Read More >